Liposomal Anthracyclines: Facing the Clinical Challenge

References

• Forssen EA, Tokes ZA. In vitro and in vivo studies with adriamycin liposomes. Biochem Biophys Res Commun 1979; 91: 1295
   PubMed Web of Science ®Google Scholar
• Szoka FC. Liposomal drug delivery: Current status and future prospects. “Membrane Fusion”, J Wilschut, D Hoekstra. Marcel Dekker Inc., New York 1991; 845
   Google Scholar
• Gabizon A. Liposomes as a drug delivery system in cancer chemotherapy. “Drug Carrier Systems” (Horizons in Biochemistry and Biophysics Series, vol 9), FH Roerdink, AM Kroon. Wiley, Chichester 1989; 185
   Google Scholar
• Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit Rev Ther Drug Carrier Systems 1987; 3: 123
   PubMed Web of Science ®Google Scholar
• Gabizon A, Chisin R, Amselem S. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer 1991; 64: 1125
   PubMed Web of Science ®Google Scholar
• Gabizon A, Goren D, Fuks Z. Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. Cancer Res 1983; 43: 4730
   PubMed Web of Science ®Google Scholar
• Gabizon A, Goren D, Barenholz Y. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models. Isr J Med Sci 1988; 24: 512
   PubMedGoogle Scholar
• MacSween RN, Anthony PP, Scheuer PJ. Pathology of the liver. Churchill-Livingstone, Edinburgh 1979
   Google Scholar
• Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6949
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Nagy JA, Dvorak JT. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Allen TM, Gabizon A. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460
   PubMed Web of Science ®Google Scholar
• Mayhew EG, Lasic DD, Babbar S. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes. Int J Cancer 1992; 51: 302
   PubMed Web of Science ®Google Scholar
• Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891
   PubMed Web of Science ®Google Scholar
• Huang SK, Mayhew E, Gilani S. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774
   PubMed Web of Science ®Google Scholar
• Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992; 52: 3255
   PubMed Web of Science ®Google Scholar
• Ogihara-Umeda I, Kojima S. Increased delivery of Gallium-67 to tumors using serum-stable liposomes. J Nuc Med 1988; 29: 516
   PubMedGoogle Scholar
• Gabizon A, Price DC, Huberty J. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res 1990; 50: 6371
   PubMed Web of Science ®Google Scholar
• Proffitt RT, Williams LE, Presant CA. Liposomal blockade of the reticuloendothelial system: Improved tumor imaging with unilamellar vesicles. Science 1983; 220: 502
   PubMed Web of Science ®Google Scholar
• Mayer LD, Tai LC, Ko DS. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989; 49: 5922
   PubMed Web of Science ®Google Scholar
• Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113: 171
   PubMed Web of Science ®Google Scholar
• Gabizon A. Liposomal anthracyclines. Hem One Clin North Am 1994, in press
   PubMedGoogle Scholar
• Siegal T, Lossos A, Gabizon A. Selective tumor localization of doxorubicin encapsulated in long-circulating liposomes in an experimental brain tumor model. Neurology 1993; 43: A360
   Google Scholar
• Williams SS, Alosco TR, Mayhew E. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 1993, in press
   Google Scholar
• Mayer LD, Tai LC, Bally MB. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1990; 1025: 143
   PubMed Web of Science ®Google Scholar
• Lasic DD, Frederik PM, Stuart MC. Gelation of liposome interior: a novel method for drug encapsulation. FEBS Lett 1992; 312: 255
   PubMed Web of Science ®Google Scholar
• Goren D, Gabizon A, Barenholz Y. The influence of physical characteristics of liposomes containing doxorubicin on their. Pharmacologic behavior. 1990; 029: 285
   Google Scholar
• Gabizon A, Bialer M, Barenholz Y. Prolongation of the circulation time of doxorubicin encapsulated in liposomes conatining a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10: 703
   PubMed Web of Science ®Google Scholar
• Bally MB, Nayar R, Masin D. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1990; 1023: 133
   PubMed Web of Science ®Google Scholar
• Merlin JL. In vitro evaluation of the association of thermosensitive liposome-encapsulated doxorubicin with hyperthermia. Eur J Cancer 1991; 27: 1031
   PubMed Web of Science ®Google Scholar
• Maruyama K, Iwatsuru M. Doxorubicin encapsulated in long-circulating thermosensitive liposomes. J. Liposome Res 1994, in press
   Google Scholar
• Rahman A. Modulation of multidrug resistance in cancer cells by liposome-encapsulated doxorubicin. J Liposome Res 1994, in press
   Google Scholar
• Perez-Soler R, Priebe W. Anthracycline antibiotics with high liposome entrapment: structural features and biological activity. Cancer Res 1990; 50: 4260
   PubMed Web of Science ®Google Scholar
• Zou Y, Horikoshi I, Ueno M. Targeting of liver tumor by administering liposomal doxrubicin into the hepatic artery. Int J Cancer 1992; 51: 232
   PubMed Web of Science ®Google Scholar
• Zou Y, Yamagishi M, Horikoshi I. Enhanced therapeutic effect aginst liver W2567 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery. Cancer Res 1993; 53: 3946
   Google Scholar
• Gabizon A, Peretz T, Sulkes A. Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study. Eur J Cancer Clin Oncol 1989; 25: 1795
   PubMedGoogle Scholar
• Rahman A, Treat J, Roh JK. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990; 8: 1093
   PubMed Web of Science ®Google Scholar
• Pestalozzi R, Schwendener R, Sauter C. Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 1992; 3: 445
   PubMed Web of Science ®Google Scholar
• Cowens JW, Creaven PJ, Greco WR. Initial clinical (Phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53: 2796
   PubMed Web of Science ®Google Scholar
• Forssen EA, Ross ME. Targeted antitumor therapy with DaunoXomeR: preclinical and clinical investigations. J Liposome Res 1994, in press
   Google Scholar
• Gabizon A., Uziely B., Kaufman B. A new generation of doxorubicin-loaded liposomes with improved localization in tumors: preclinical and clinical studies. “Proceedings 4th Int'l Congress on Anti-Cancer Chemotherapy”., D Khayat. Springer Verlag, Paris 1993, in press
   Google Scholar